Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

BACKGROUND: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti‐von Willebrand Factor Nanobody(®), is effective for treating aTTP episodes and is well tolerated. OBJECTIVES AND METHODS: In the phase 3 HERCULES t...

Descripción completa

Detalles Bibliográficos
Autores principales: Knoebl, Paul, Cataland, Spero, Peyvandi, Flora, Coppo, Paul, Scully, Marie, Kremer Hovinga, Johanna A., Metjian, Ara, de la Rubia, Javier, Pavenski, Katerina, Minkue Mi Edou, Jessica, De Winter, Hilde, Callewaert, Filip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
THROMBOSIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027866/
https://www.ncbi.nlm.nih.gov/pubmed/31691462
http://dx.doi.org/10.1111/jth.14679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027866/
https://www.ncbi.nlm.nih.gov/pubmed/31691462
http://dx.doi.org/10.1111/jth.14679

Ejemplares similares